Market Closed -
Toronto S.E.
09:30:00 2024-06-26 am EDT
|
5-day change
|
1st Jan Change
|
0.28
CAD
|
+3.70%
|
|
-5.08%
|
+40.00%
|
Fiscal Period: July |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9.874
|
21.69
|
17.76
|
19.18
|
16.3
|
13.6
|
Enterprise Value (EV)
1 |
28.73
|
35.7
|
34.25
|
30.41
|
36.23
|
12.25
|
P/E ratio
|
-1.88
x
|
-2.16
x
|
-3.87
x
|
29.3
x
|
-3.57
x
|
0.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.38
x
|
0.94
x
|
0.78
x
|
0.79
x
|
0.57
x
|
84.4
x
|
EV / Revenue
|
1.1
x
|
1.55
x
|
1.5
x
|
1.25
x
|
1.26
x
|
76
x
|
EV / EBITDA
|
-147
x
|
148
x
|
68.1
x
|
16.4
x
|
24.2
x
|
-4.09
x
|
EV / FCF
|
38.2
x
|
6.77
x
|
-6.36
x
|
6.68
x
|
-13.8
x
|
-2.31
x
|
FCF Yield
|
2.62%
|
14.8%
|
-15.7%
|
15%
|
-7.23%
|
-43.2%
|
Price to Book
|
-2.38
x
|
-3.52
x
|
-5.94
x
|
4.9
x
|
-80.4
x
|
0.82
x
|
Nbr of stocks (in thousands)
|
42,931
|
86,761
|
118,421
|
147,541
|
148,141
|
159,966
|
Reference price
2 |
0.2300
|
0.2500
|
0.1500
|
0.1300
|
0.1100
|
0.0850
|
Announcement Date
|
11/30/18
|
11/28/19
|
11/30/20
|
11/29/21
|
11/25/22
|
11/28/23
|
Fiscal Period: Juli |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
26.08
|
23.09
|
22.89
|
24.36
|
28.82
|
0.1611
|
EBITDA
1 |
-0.1951
|
0.2415
|
0.5032
|
1.856
|
1.498
|
-2.999
|
EBIT
1 |
-1.193
|
-0.1207
|
-0.1011
|
1.439
|
1.183
|
-3.309
|
Operating Margin
|
-4.58%
|
-0.52%
|
-0.44%
|
5.91%
|
4.11%
|
-2,053.85%
|
Earnings before Tax (EBT)
1 |
-5.71
|
-7.438
|
-5.347
|
0.3427
|
-4.646
|
2.473
|
Net income
1 |
-5.212
|
-8.516
|
-4.31
|
0.5615
|
-4.562
|
16.14
|
Net margin
|
-19.98%
|
-36.88%
|
-18.83%
|
2.31%
|
-15.83%
|
10,015.99%
|
EPS
2 |
-0.1222
|
-0.1158
|
-0.0387
|
0.004442
|
-0.0308
|
0.1083
|
Free Cash Flow
1 |
0.753
|
5.277
|
-5.388
|
4.555
|
-2.62
|
-5.295
|
FCF margin
|
2.89%
|
22.85%
|
-23.54%
|
18.7%
|
-9.09%
|
-3,286.3%
|
FCF Conversion (EBITDA)
|
-
|
2,184.75%
|
-
|
245.41%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
811.19%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/30/18
|
11/28/19
|
11/30/20
|
11/29/21
|
11/25/22
|
11/28/23
|
Fiscal Period: July |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
18.9
|
14
|
16.5
|
11.2
|
19.9
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
1.34
|
Leverage (Debt/EBITDA)
|
-96.63
x
|
58
x
|
32.76
x
|
6.05
x
|
13.31
x
|
-
|
Free Cash Flow
1 |
0.75
|
5.28
|
-5.39
|
4.55
|
-2.62
|
-5.3
|
ROE (net income / shareholders' equity)
|
312%
|
167%
|
89%
|
686%
|
-246%
|
7.59%
|
ROA (Net income/ Total Assets)
|
-2.69%
|
-0.37%
|
-0.35%
|
4.27%
|
2.91%
|
-8.19%
|
Assets
1 |
193.7
|
2,318
|
1,229
|
13.15
|
-156.9
|
-196.9
|
Book Value Per Share
2 |
-0.1000
|
-0.0700
|
-0.0300
|
0.0300
|
-0
|
0.1000
|
Cash Flow per Share
2 |
0.0200
|
0.0100
|
0.0200
|
0.0100
|
0.0200
|
0.0300
|
Capex
1 |
0.33
|
0.39
|
0.89
|
0.05
|
0.05
|
0
|
Capex / Sales
|
1.26%
|
1.7%
|
3.89%
|
0.2%
|
0.16%
|
2.91%
|
Announcement Date
|
11/30/18
|
11/28/19
|
11/30/20
|
11/29/21
|
11/25/22
|
11/28/23
|
|
1st Jan change
|
Capi.
|
---|
| +40.00% | 34.68M | | +23.13% | 52.73B | | +37.49% | 39B | | -8.73% | 38.52B | | +28.09% | 30.38B | | -12.26% | 26.39B | | +10.57% | 26.08B | | +45.05% | 14.15B | | +32.23% | 12.6B | | -6.56% | 11.51B |
Other Biotechnology & Medical Research
|